CML at the 2018 ASH meeting —selected presentations
SummaryTreatment recommendations in chronic myeloid leukemia (CML) treatment have not changed substantially since treatment-free remission (TFR) has become a therapeutic option. Hence, allowing more patients to enter TFR is gaining significance. Although, Asciminib as a first-in-class new type of tyrosine kinase inhibitor (TKI) is in clinical development, currently combination treatment with TKIs and Interferon-alpha2b appears the best option to deepen molecular response and broaden the basis of potential TFR candidates. Improving the chances of a first successful TFR has to be the primary goal in TFR optimization as even re-induction of a deep molecular response after TFR failure using second generation TKIs shows disillusioning results.
Authors: Miyoshi I, Mori M, Yamasaki I, Daibata M PMID: 32224562 [PubMed - in process]
New England Journal of Medicine,Volume 382, Issue 14, Page 1378-1379, April 2020.
A 34-year-old man with chronic myelogenous leukemia status post allogeneic hematopoietic stem cell transplant (HSCT) on tacrolimus for graft-vs-host disease prophylaxis, presented with a 1-week history of fevers and severe headaches. Brain magnetic resonance imaging (MRI) demonstrated numerous small focal lesions in the left basal ganglia and left temporal lobe with a ring pattern, as well as a large lesion in the left occipital lobe with mild leptomeningeal enhancement (Figure 1). Cerebrospinal fluid (CSF) analysis revealed lymphocytic pleocytosis, and Toxoplasma gondii was detected by polymerase chain reaction (PCR).
sco Salvo Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia (CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case study was performed using AE reports registered in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to compare the risk of CV event reports related to TKIs indicated in the management of chronic myeloid leukemia (CML). Disproportionality of CV event-related TKIs was computed using the Reporting Odds Ratio (ROR) as a measure of potential risk increase. Nilotinib accounts for more than half of reported ...
AbstractBackgroundSALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs).Methods and resultsImmunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+ (1&ndas...
We present the first reported case of GA in a patient with essential thrombocythemia (ET). Future work investigating the shared pathophysiology of GA ‐associated CML and ET may improve our understanding of GA pathophysiology and treatment. AbstractThe only myeloproliferative neoplasm associated with generalized granuloma annulare (GA) is chronic myelogenous leukemia (CML). We present the first reported case of GA in a patient with essential thrombocythemia (ET). Future work investigating the shared pathophysiology of GA ‐associated CML and ET may improve our understanding of GA pathophysiology and treatment.
Authors: Fujita M, Kamachi K, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S Abstract Patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) are often asymptomatic and thus can remain undiagnosed until they become symptomatic due to progression to the accelerated phase (AP) or transformation to acute leukemia (leukemic transformation; LT). We herein report the case of a previously healthy 38-year-old man who had hyperleukocytosis with dysplastic myeloid precursor cells and severe disseminated intravascular coagulation. ...
PMID: 32200529 [PubMed - as supplied by publisher]
Publication date: Available online 17 March 2020Source: Cancer GeneticsAuthor(s): Jaime L. Lopes, Matthew Webley, Beth A. Pitel, Kathryn E. Pearce, James B. Smadbeck, Sarah H. Johnson, George Vasmatzis, William R. Sukov, Patricia T. Greipp, Nicole L. Hoppman, Rhett P. Ketterling, Linda B. Baughn, Laura Finn, Jess F. Peterson
(Duke-NUS Medical School) Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research's (A*STAR's) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia, known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression.